EUCTR2010-021898-36-IT进行中（未招募）不适用
Tandem high-dose chemotherapy (HDCT) with peripheral-blood stem-cell rescue for patients with metastatic germ-cell tumors failing first-line treatment. - High-dose chemotherapy for relapsed germ-cell cancer
ISTITUTO NAZIONALE PER LA CURA TUMORI0 个研究点开始时间: 2010年11月9日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Age = 18 years Male gender Histologic or clinical diagnosis of GCT. Unequivocal progression of measurable disease (measurable disease will consist of abnormalities on 2 dimensional imaging or raised tumor markers) following one line of cisplatin-based chemotherapy. IGCCCG-2 Good, Intermediate, Poor Relapser category. WBC = 2000/?L with ANC = 1500/?L. Platelets = 100.000/?L. AST/ALT <2x ULN unless due to hepatic metastases in which case levels <5xULN are allowed. Total Bilirubin <1.5x ULN. Adequate cardiac function (EF = 50% at echocardiogram). Negative Serology for the following infectious diseases: HBV, HCV, HIV, CMV. Written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Failure to meet any of the above inclusion criteria. Patients falling into the prognostic categories of Very Good” and/or Very Poor” relapsers according to the IGCCCG-2 scoring system. More than one prior line of cisplatin-based chemotherapy. Prior treatment with high-dose chemotherapy. =7 cycles of prior cisplatin-based chemotherapy. Concurrent treatment with other cytotoxic drugs or targeted therapies. Prior radiation therapy (other than to the brain) within 14 days of day 1 of protocol chemotherapy. Inability to comply with the treatment protocol or to undergo the specified follow-up tests for safety or effectiveness. The existence of a concurrent malignancy (other than non-melanoma skin cancer). Patients with a prior malignancy, but at least 5 years since any evidence of disease will be allowed to enroll. Patients with late relapses. For high-dose cycle 2, the patient should not have evidence of progressive disease on imaging or have rapidly rising serum tumor markers following high-dose cycle 1. Serious infections (G>2 NCI-CTC v.4.0). Serum positivity for either HBV, HCV, HIV, CMV.
研究者
相似试验
Unknown
2 期
High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to First-Line TherapyBrain and Central Nervous System TumorsExtragonadal Germ Cell TumorTesticular Germ Cell TumorNCT01172912Fondazione IRCCS Istituto Nazionale dei Tumori, Milano47
进行中（未招募）
1 期
Concurrent helical tomotherapy with chemotherapy in unresectable stage III non-small cell lung cancer (NSCLC):a phase I/II trial of radiation dose escalation and fixed dose chemotherapy. - TomoCTstage III locally advanced non small cell lung cancer (LA-NSCLC)MedDRA version: 8.1Level: LLTClassification code 10029519Term: Non-small cell lung cancer stage IIIEUCTR2006-003708-21-BEAZ-VUB30
进行中（未招募）
2 期
Intensity modulated radiation therapy in Patients with locally advanced inoperable gall bladder and pancreatic cancerCTRI/2016/08/007129Tata Memorial Hospital60
进行中（未招募）
不适用
Treatment With Chemotherapy and Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)Diffuse Large B Cell Lymphoma and HIV InfectionEUCTR2006-003750-23-ESFundación PETHEMA
已完成
2 期
High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF IITesticular NeoplasmsNCT00231582Assistance Publique - Hôpitaux de Paris50